SINAGRA, GIANFRANCO
 Distribuzione geografica
Continente #
NA - Nord America 4.255
AS - Asia 3.055
EU - Europa 2.231
SA - Sud America 697
AF - Africa 101
OC - Oceania 8
Totale 10.347
Nazione #
US - Stati Uniti d'America 4.072
SG - Singapore 1.154
CN - Cina 804
IT - Italia 647
RU - Federazione Russa 645
BR - Brasile 519
VN - Vietnam 488
DE - Germania 206
HK - Hong Kong 194
GB - Regno Unito 150
FR - Francia 112
CA - Canada 104
IE - Irlanda 77
AR - Argentina 72
FI - Finlandia 72
IN - India 72
NL - Olanda 62
PL - Polonia 59
MX - Messico 54
ZA - Sudafrica 49
TR - Turchia 47
BD - Bangladesh 42
PK - Pakistan 41
ES - Italia 37
ID - Indonesia 35
JP - Giappone 34
UA - Ucraina 34
SE - Svezia 32
EC - Ecuador 31
IQ - Iraq 30
CO - Colombia 28
AT - Austria 25
LT - Lituania 20
IL - Israele 19
VE - Venezuela 19
SA - Arabia Saudita 17
UZ - Uzbekistan 15
BE - Belgio 12
AE - Emirati Arabi Uniti 11
EG - Egitto 10
MA - Marocco 10
CL - Cile 9
KE - Kenya 9
CH - Svizzera 8
TN - Tunisia 8
JO - Giordania 7
OM - Oman 7
SI - Slovenia 6
BO - Bolivia 5
JM - Giamaica 5
KZ - Kazakistan 5
MY - Malesia 5
PE - Perù 5
PY - Paraguay 5
AU - Australia 4
AZ - Azerbaigian 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
NZ - Nuova Zelanda 4
PA - Panama 4
PH - Filippine 4
PT - Portogallo 4
RO - Romania 4
UY - Uruguay 4
AL - Albania 3
DO - Repubblica Dominicana 3
NP - Nepal 3
SN - Senegal 3
TW - Taiwan 3
CY - Cipro 2
GR - Grecia 2
HR - Croazia 2
KW - Kuwait 2
NO - Norvegia 2
PR - Porto Rico 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BG - Bulgaria 1
BW - Botswana 1
BZ - Belize 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
GP - Guadalupe 1
HU - Ungheria 1
IR - Iran 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
NG - Nigeria 1
Totale 10.343
Città #
Dallas 1.836
Singapore 666
San Jose 384
Ashburn 359
Beijing 274
Hong Kong 186
Ho Chi Minh City 177
Los Angeles 107
Moscow 104
Hanoi 95
New York 89
Milan 88
Dublin 76
Santa Clara 68
Council Bluffs 62
Chandler 61
Munich 58
Rome 57
São Paulo 56
Lauterbourg 51
Orem 50
Warsaw 48
The Dalles 47
Hefei 45
Helsinki 39
Frankfurt am Main 38
Johannesburg 37
Montreal 36
Boardman 31
Chennai 31
Buffalo 30
San Mateo 30
Tokyo 30
Brooklyn 29
London 27
Denver 25
Mexico City 25
Houston 24
Amsterdam 23
Ottawa 23
Pisa 23
Poplar 23
Beauharnois 22
Fairfield 22
Lappeenranta 22
Haiphong 21
Phoenix 21
Seattle 21
Cambridge 20
Nuremberg 20
Bologna 19
Da Nang 19
Istanbul 19
Boston 18
Portsmouth 17
Chicago 16
Rio de Janeiro 16
Stockholm 16
West Jordan 16
Brasília 15
Genoa 15
Naples 15
Ankara 14
Atlanta 14
San Francisco 14
Stevenage 14
Tashkent 14
Tel Aviv 14
Biên Hòa 13
Krefeld 13
Querétaro 13
Wilmington 13
Belo Horizonte 12
Florence 11
Guarulhos 11
Lahore 11
Lawrence 11
Manchester 11
Paris 11
Porto Alegre 11
Turin 11
Turku 11
Washington 11
Bad Bellingen 10
Brussels 10
Dong Ket 10
Medellín 10
Ninh Bình 10
Buenos Aires 9
Jeddah 9
Nairobi 9
New Delhi 9
Quito 9
Shenzhen 9
Vienna 9
Bari 8
Guayaquil 8
Livorno 8
Nocera Inferiore 8
Shanghai 8
Totale 6.349
Nome #
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 698
Impact of GFR Estimation Formulas on MECKI Score Performance and Prognostic Accuracy in Heart Failure: The MECKI-RENAL Study 465
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 395
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: Insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in Italian cardiac care units Registry 295
[Ten perspectives for research and innovation in cardiac amyloidosis] 278
Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction 278
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 273
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 261
Cardiac and neuromuscular features of patients with LMNA-related cardiomyopathy 242
[Transcatheter devices for chronic heart failure: state of the art] 241
Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test 220
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 217
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 216
Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry 211
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 209
Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension 209
Roles of periodic breathing and isocapnic buffering period during exercise in heart failure 208
Valvular heart disease in patients with cardiac amyloidosis 206
Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score 205
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 201
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 200
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 198
Heart failure patients with improved ejection fraction: Insights from the MECKI score database 195
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 195
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 190
Inferior Vena Cava Edge Tracking Echocardiography: A Promising Tool with Applications in Multiple Clinical Settings 190
Association between implantable defibrillator-detected sleep apnea and atrial fibrillation: The DASAP-HF study 189
Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group 187
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 180
Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set 175
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 172
Pressure-volume relationship by pharmacological stress cardiovascular magnetic resonance 168
The chronic heart failure evolutions: Different fates and routes 162
Myocarditis and pericarditis during COVID-19 pandemic: a study of the Italian Society of Cardiology 158
Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension 155
Change in prevalence of ATTR variants in Italy: results from a national survey 152
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 152
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis 149
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 149
Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension 142
Cardiac amyloidosis: when to suspect and how to confirm 139
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 137
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 123
Tafamidis in the Treatment of ATTR-related Cardiomyopathy 95
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy 82
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis 66
Changes in CMR-derived ventricular strain, fibrosis progression and outcomes in hypertrophic cardiomyopathy 58
Serum Transthyretin Before and After Starting Tafamidis as Outcome Predictors in ATTR Cardiomyopathy 54
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry 51
MECKI score thresholds for heart transplantation referral of ambulatory heart failure patients 48
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population 47
Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: the MECKI-RENAL study 46
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 46
Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC) 46
Analysis of Calcium Scores in Severe Aortic Stenosis Patients With and Without Cardiac Amyloidosis 44
Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: The MECKI-RENAL study 43
Analysis of Calcium Scores in Severe Aortic Stenosis Patients With and Without Cardiac Amyloidosis: The CAUSATIVE Study 40
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis 40
Current Standards and Perspectives in Proteomics for Cardiac Amyloidosis 39
Linda Pagura 1, Aldostefano Porcari 2, Matteo Cameli 3, Elena Biagini 4, Marco Canepa 5, Lia Crotti 6, Massimo Imazio 7, Cinzia Forleo 8, Rita Pavasini 9, Giuseppe Limongelli 10, Stefano Perlini 11, Marco Metra 12, Giuseppe Boriani 13, Michele Emdin 14, Gianfranco Sinagra 2, Marco Merlo 15; ACTIVE study group 39
Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies 39
Electrocardiographic abnormalities in patients with cardiomyopathies 34
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy 33
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy 29
Diagnostic Role of Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations 20
Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact 14
Totale 10.438
Categoria #
all - tutte 43.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.027


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 0 0 0 0 5 30 18
2021/2022174 19 25 2 19 0 6 19 25 10 28 7 14
2022/2023204 12 21 3 15 22 23 5 23 52 1 17 10
2023/2024332 10 7 39 23 5 16 13 27 43 33 33 83
2024/20251.828 31 81 137 52 112 90 243 397 160 70 265 190
2025/20267.799 322 973 1.817 907 698 515 727 510 783 547 0 0
Totale 10.438